A detailed history of Redmile Group, LLC transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, Redmile Group, LLC holds 4,483,016 shares of NRIX stock, worth $93.6 Million. This represents 2.6% of its overall portfolio holdings.

Number of Shares
4,483,016
Previous 3,256,519 37.66%
Holding current value
$93.6 Million
Previous $33.6 Million 96.09%
% of portfolio
2.6%
Previous 1.33%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$7.77 - $15.66 $9.53 Million - $19.2 Million
1,226,497 Added 37.66%
4,483,016 $65.9 Million
Q4 2023

Feb 14, 2024

BUY
$4.25 - $10.71 $1.7 Million - $4.28 Million
399,210 Added 13.97%
3,256,519 $33.6 Million
Q2 2023

Aug 14, 2023

BUY
$8.7 - $13.28 $938,947 - $1.43 Million
107,925 Added 3.93%
2,857,309 $28.5 Million
Q1 2023

May 15, 2023

SELL
$8.56 - $13.26 $2.15 Million - $3.33 Million
-251,400 Reduced 8.38%
2,749,384 $24.4 Million
Q4 2022

Feb 14, 2023

SELL
$9.86 - $14.59 $58,174 - $86,081
-5,900 Reduced 0.2%
3,000,784 $32.9 Million
Q2 2022

Aug 15, 2022

SELL
$7.88 - $14.82 $95,348 - $179,322
-12,100 Reduced 0.4%
3,006,684 $38.1 Million
Q1 2022

May 16, 2022

BUY
$12.94 - $29.65 $782,870 - $1.79 Million
60,500 Added 2.05%
3,018,784 $42.3 Million
Q4 2021

Feb 14, 2022

SELL
$26.43 - $34.5 $3.56 Million - $4.65 Million
-134,793 Reduced 4.36%
2,958,284 $85.6 Million
Q3 2021

Nov 15, 2021

SELL
$22.71 - $36.69 $2.2 Million - $3.56 Million
-97,000 Reduced 3.04%
3,093,077 $92.7 Million
Q2 2021

Aug 16, 2021

SELL
$24.21 - $35.89 $3 Million - $4.45 Million
-124,040 Reduced 3.74%
3,190,077 $84.6 Million
Q1 2021

May 17, 2021

BUY
$26.98 - $50.17 $12.6 Million - $23.5 Million
467,992 Added 16.44%
3,314,117 $103 Million
Q4 2020

Feb 16, 2021

BUY
$22.85 - $48.44 $5.77 Million - $12.2 Million
252,555 Added 9.74%
2,846,125 $93.6 Million
Q3 2020

Nov 16, 2020

BUY
$16.05 - $34.91 $41.6 Million - $90.5 Million
2,593,570 New
2,593,570 $90.5 Million

Others Institutions Holding NRIX

About Nurix Therapeutics, Inc.


  • Ticker NRIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 47,147,800
  • Market Cap $984M
  • Description
  • Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...
More about NRIX
Track This Portfolio

Track Redmile Group, LLC Portfolio

Follow Redmile Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Redmile Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Redmile Group, LLC with notifications on news.